Drug Profile
INS 117548
Alternative Names: INS117548Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Inspire Pharmaceuticals
- Developer Merck & Co
- Class
- Mechanism of Action Actin modulators; Rho-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Glaucoma; Ocular hypertension; Ocular inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Glaucoma in USA (Ophthalmic, Drops)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Ocular-hypertension in USA (Ophthalmic, Drops)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Ocular-inflammation in USA (Ophthalmic, Drops)